Physician profile
Ruoru Wong
NPI 1003156449
$9,557.57
in general payments reported to CMS, 2019-2025
17 companies · $4,568 in 2025
The $4,568 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,471 · 2022: $676 · 2023: $1,125 · 2024: $1,717 · 2025: $4,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,409.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $2,401.77 | 2021-2025 | Veltassa, Korsuva, Zemaira |
| Aurinia Pharma U.S., INC. | $1,680.23 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $1,009.61 | 2021-2024 | Lokelma |
| Akebia Therapeutics INC | $1,008.31 | 2021-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $665.58 | 2021-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $499.40 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $485.51 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.48 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $361.06 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Lilly USA, LLC | $319.56 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $214.88 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $136.77 | 2021-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $118.40 | 2022 | |
| Novo Nordisk INC | $114.92 | 2025 | Ozempic |
| Ani Pharmaceuticals, INC. | $106.32 | 2023 | Purified Cortrophin Gel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.56 | 2023 | Tavneos |
| Paratek Pharmaceuticals, INC. | $17.21 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruoru Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.